Finanzen von Zomedica Corp (ZOM)ZOMZomedica Corp

Zomedica Corp (ZOM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics, accounting for 93.2% of total sales, equivalent to $5.71M. Another important revenue stream is Therapeutics. Understanding this composition is critical for investors evaluating how ZOM navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Zomedica Corp maintains a gross margin of 72.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -106.33%, while the net margin is -95.71%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZOM converts its operational activities into shareholder value.

In the context of the broader market, ZOM competes directly with industry leaders such as ACHV and IMUX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ZOM's gross margin of 72.32% stands against ACHV's N/A and IMUX's N/A. Such benchmarking helps identify whether Zomedica Corp is trading at a premium or discount relative to its financial performance.